natgillin/translations-raw huggingface dataset:
The 300 ml glass bottle of Briviact is packed in a cardboard box containing a 10 ml oral syringe and an adaptor for the syringe.
Staklena boca lijeka Briviact od 300 ml pakirana je u kutiju koja sadrži štrcaljku za usta od 10 ml i nastavak za štrcaljku.
The 300 ml glass bottle of Keppra (for children aged 4 years and above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml) and an adaptor for the syringe.
Staklena boca od 300 ml Keppre (za djecu u dobi od 4 godine i stariju, adolesc ente i odrasle) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 10 ml (s oznakom na svakih 0,25 ml) i nastavak za štrcaljku.
The 320 mg/40 mg tablets have two ’σ’ letters on one side and come in blisters containing 3, 6, 9 or 12 tablets.
Tablete od 320 mg/40 mg imaju dva slova ‘σ’ na jednoj strani i isporučuju se u blisterima koji sadrže 3, 6, 9 ili 12 tableta.
The 36 patients had a median age of 14.5 years and were 55.6% female, 88.9% Black, and 11.1% Asian.
Za 36 bolesnika je medijan dobi bio 14,5 godina i bilo je 55,6% žena, 88,9% crnaca i 11,1% azijata.
The 4 mg capsule is a yellowish red body and yellowish red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body.
Kapsula od 4 mg ima žućkasto-crveno tijelo i žućkasto-crvenu kapicu, duljine je približno 14,3 mm, s oznakom “Є” otisnutom crnom tintom na kapici, i “LENV 4 mg” na tijelu.
The 4 mg prolonged-release tablets are oval and green, hard tablets, debossed with 4MG on one side and 503 on the other side.
Tablete s produljenim oslobađanjem od 4 mg ovalne su i zelene, tvrde tablete s utisnutom oznakom 4MG na jednoj strani i 503 na drugoj strani.
The 4 yellow tablets are inactive tablets that do not contain hormones and are called placebo tablets.
Četiri žute tablete su neaktivne tablete koje ne sadrže hormone i nazivaju se tablete placeba.
The 4-hydroxy-propranolol metabolite was quantified, its plasma exposure accounting for less than 7% of the parent drug exposure.
4-hidroksi-propranolol metabolit je bio kvantificiran, njegova izloženost u plazmi čini manje od 7% izloženosti matičnog lijeka.
The 4-oxo and 4- hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Epimerni par 4-okso- i 4-hidroksimetabolita glavni su metaboliti s antivirusnim djelovanjem, no njihov je udio u ukupno izmjerenoj radioaktivnosti u plazmi neznatan.
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Epimerni par 4-okso- i 4- hidroksimetabolita glavni su metaboliti s antivirusnim djelovanjem, no njihov je udio u ukupno izmjerenoj radioaktivnosti u plazmi bio neznatan.
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Epimerni par 4-okso- i 4- hidroksimetabolita glavni su metaboliti s antivirusnim djelovanjem, no njihov je udio u ukupno izmjerenoj radioaktivnosti u plazmi neznatan.
The 4-week treatment initiation pack of Xarelto is dedicated to patients who will transition from 15 mg twice daily to 20 mg once daily from Day 22 onwards (see section 6.5).
Pakiranje lijeka Xarelto za prva 4 tjedna početnog liječenja namijenjeno je bolesnicima koji će preći s doze od 15 mg dvaput na dan na dozu od 20 mg jedanput na dan od 22. dana nadalje (vidjeti dio 6.5).
The 4-week, double-blind period was followed by an 8-week, open-label period during which methylnaltrexone bromide was to be used as needed, but no more frequently than once daily.
Nakon 4- tjednog, dvostruko slijepog razdoblja slijedilo je 8-tjedno, otvoreno razdoblje tijekom kojeg je metilnaltreksonbromid primjenjivan po potrebi, ali ne češće od jedanput dnevno.
The 40 g sachet is sufficient to treat a total of 5,000 kg of pigs (e.g.
Vrećica od 40 g dovoljna je za liječenje svinja ukupne mase 5000 kg (npr.
The 40 g sachet is sufficient to treat a total of 5,000 kg of pigs (e.g.
Vrećica od 40 g dovoljna je za liječenje svinja ukupne težine 5000 kg (npr.
The 40 mg capsules are orange and blue and are printed with ’40 mg’ and the code ‘9545’.
Kapsule od 40 mg su narančaste i plave boje s otisnutom oznakom ‘40 mg’ i oznakom ‘9545’.
The 40 mg hard capsule is opaque with a white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
EMEND 40 mg tvrda kapsula je neprozirna, s bijelim tijelom i žućkastom kapicom te poprečno otisnutim crnim oznakama "464" i "40 mg" na tijelu kapsule.
The 40 mg/ml solution for injection should not be handled by pregnant women or women attempting to conceive as it may affect the development of the baby in the womb.
Otopinom za injekciju od 40 mg/ml ne smiju rukovati trudnice niti žene koje namjeravaju zanijeti jer može utjecati na razvoj ploda u maternici.
The 400 g sachet is sufficient to treat a total of 50,000 kg of pigs (e.g.
Vrećica od 400 g dovoljna je za liječenje svinja ukupne mase 50 000 kg (npr.
The 400 g sachet is sufficient to treat a total of 50,000 kg of pigs (e.g.
Vrećica od 400 g dovoljna je za liječenje svinja ukupne tjelesne mase 50 000 kg (npr.
The 420 mg dose once monthly or every 2 weeks should be delivered using three pre-filled pens administered consecutively within 30 minutes.
Dozu od 420 mg treba primijeniti pomoću tri napunjene brizgalice uzastopce unutar 30 minuta, jedanput mjesečno ili svaka 2 tjedna.
The 420 mg dose once monthly or every 2 weeks should be delivered using three pre-filled syringes administered consecutively within 30 minutes.
Dozu od 420 mg treba primijeniti pomoću tri napunjene štrcaljke uzastopce unutar 30 minuta, jedanput mjesečno ili svaka 2 tjedna.
The 45 mg hard capsule consists of a grey opaque body bearing the imprint “ROCHE” and a grey opaque cap bearing the imprint “45 mg”.
Tvrda kapsula od 45 mg se sastoji od sivog neprozirnog tijela s natpisom "ROCHE" i sive neprozirne kapice s natpisom "45 mg".
The 48-week primary endpoint data showed that the combination of emtricitabine, tenofovir disoproxil and efavirenz provided superior antiviral efficacy as compared with the fixed combination of lamivudine and zidovudine with efavirenz as shown in Table 4.
Podaci za primarnu mjeru ishoda nakon 48 tjedana pokazali su da je kombinacija emtricitabina, tenofovirdizoproksila i efavirenza imala veću antivirusnu djelotvornost u usporedbi s fiksnom kombinacijom lamivudina i zidovudina s efavirenzom, kako je prikazano u Tablici 4.
The 48-week primary endpoint data showed that the combination of emtricitabine, tenofovir disoproxil fumarate and efavirenz provided superior antiviral efficacy as compared with the fixed combination of lamivudine and zidovudine with efavirenz as shown in Table 4.
Podaci primarne mjere ishoda nakon 48 tjedana pokazali su da je kombinacija emtricitabina, tenofovirdizoproksilfumarata i efavirenza imala veću antivirusnu djelotvornost u usporedbi s fiksnom kombinacijom lamivudina i zidovudina s efavirenzom, kako je pokazano u Tablici 4.
The 49 mg/51 mg and 97 mg/103 mg tablets are also supplied in multipacks of 168 tablets (3 packs of 56 tablets) or 196 tablets (7 packs of 28 tablets).
Tablete od 49 mg/51 mg i 97 mg/103 mg se također isporučuju u višestrukim pakiranjima od 168 tableta (3 pakiranja od po 56 tableta) ili 196 tableta (7 pakiranja od po 28 tableta).
The 49 mg/51 mg tablet coating contains hypromellose, titanium dioxide (E171), Macrogol 4000, talc, iron oxide red (E172) and iron oxide yellow (E172).
Ovojnica tablete od 49 mg/51 mg sadrži hipromelozu, titanijev dioksid (E171), makrogol 4000, talk, željezov oksid crveni (E172) i željezov oksid žuti (E172).
The 5 mg film-coated tablets are white to off-white, capsule shaped (9.6 x 4.54 mm), biconvex tablets plain on one side and embossed with “5” on the other side.
Filmom obložene tablete od 5 mg su bijele do gotovo bijele, bikonveksne tablete u obliku kapsule (9,6 x 4,54 mm), glatke s jedne strane i s utisnutim “5” s druge strane.
The 5 mg film-coated tablets are white to off-white, oval-oblong film-coated tablets with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
Filmom obložene tablete od 5 mg su bijele do gotovo bijele, ovalno duguljaste filmom obložene tablete s utisnutom oznakom ‘5’ na jednoj strani i ‘MEM’ na drugoj strani.
The 5 mg film-coated tablets are white, oblong, coated tablets, debossed with "MT" on one side and "5" on the other side.
Filmom obložene tablete od 5 mg su bijele, duguljaste, obložene tablete, s utisnutom oznakom ‘MT’ na jednoj strani i ‘5’ na drugoj strani.
The 5 mg film-coated tablets are white, oval shaped, biconvex film-coated tablets, 8 mm x 4.5 mm in size, with the marking “M5” engraved on one side.
Filmom obložene tablete od 5 mg su bijele, bikonveksne, ovalnog oblika, veličine 8 mm x 4,5 mm i s ugraviranom oznakom „M5” na jednoj strani.
The 5 mg sublingual tablets are round white to off-white tablets marked with “5” on one side.
Sublingvalne tablete od 5 mg su bijele do gotovo bijele okrugle tablete, s utisnutom oznakom "5" na jednoj strani.
The 5 mg tablets also contain red iron oxide (E172), yellow iron oxide (E172) and black iron oxide (E172).
Tableta od 5 mg sadrži također crveni željezov oksid (E172), žuti željezov oksid (E172) i crni željezov oksid (E172).
The 5 mg tablets have a score line that enables them to be divided into two halves each containing 2.5 mg ivabradine).
Tablete od 5 mg mogu imati razdjelnu liniju koja omogućuje da se tablete podjele na dvije polovice tako da svaka sadrži 2,5 mg ivabradina).
The 5 ml oral syringe (the largest oral syringe), is marked from 1 ml to 5 ml with minor 0.2- ml graduations.
Štrcaljka za usta od 5 ml (najveća štrcaljka) obilježena je od 1 do 5 ml u koracima od 0,2 ml.
The 5 ml oral syringe has graduations for 0.2 ml solution (= 2 mg itraconazole).
Peroralna šprica od 5 ml ima graduacije za 0,2 ml otopine (= 2 mg itrakonazola).
The 5 patients who died due to sepsis (4 due to urinary tract infection and 1 secondary to decubitus ulcers), all had advanced Multiple Sclerosis disease and multiple drug therapy.
5 bolesnika koji su umrli od sepse (4 zbog infekcije mokraćnog sustava i 1 zbog dekubitusa) bolovali su od uznapredovale multiple skleroze i liječili se uzimanjem više lijekova.
The 5 randomised studies investigated a total of 3734 patients with metastatic colorectal cancer, in whom EGFR expression was detectable and who had an ECOG performance status of ≤ 2.
Pet randomiziranih ispitivanja obuhvaćala su ukupno 3734 bolesnika s metastatskim kolorektalnim karcinomom, kod kojih se mogla detektirati ekspresija EGFR-a i kod kojih je indeks općeg statusa po ECOG skali bio ≤ 2.
The 5- aminovaleric acid is the major phase I inactive metabolite and is found in urine and serum.
Glavni neaktivni metabolit faze I je 5-aminovaleratna kiselina, a nalazi se u urinu i serumu.
The 50 mg capsules are orange (black imprint “ASK001” and “50mg”).
Kapsule od 50 mg su narančaste boje (crnim natpisom "ASK001" i "50 mg").
The 50 mg vial contains an overfill to allow the withdrawal of 50 mg when reconstituted if following the directions described below.
Bočica od 50 mg sadrži suvišak kako bi se omogućilo izvlačenje 50 mg lijeka kada se pripremi za primjenu prema uputama opisanima u nastavku.
The 50 ml syringe containing the diluted Removab solution for infusion is installed in the precision pump.
Štrcaljka od 50 ml koja sadrži razrijeđenu Removab otopinu za infuziju namjesti se na preciznu pumpu.
The 50 ml syringe is closed with a cap and shaken gently to mix the solution.
Štrcaljka od 50 ml se zatvori zatvaračem i nježno protrese kako bi se otopina promiješala.
The 50 ml syringe is inserted in the infusion pump.
Štrcaljka od 50 ml umetne se u infuzijsku pumpu.
The 50 patients who achieved a clinical response after a 12-week open-label run-in were randomized to Kineret (25 patients) or placebo (25 patients), administered daily for an additional 16 weeks.
50 bolesnika u kojih je postignut klinički odgovor nakon 12 tjedana otvorene, početne faze ispitivanja randomizirani su u skupine koje su daljnjih 16 tjedana dnevno primale Kineret (25 ispitanika) ili placebo (25 ispitanika).
The 50% effective concentration (EC50) values of sofosbuvir and velpatasvir against full-length or chimeric replicons encoding NS5B and NS5A sequences from the laboratory strains are presented in Table 4.
Vrijednosti 50 % učinkovite koncentracije (EC50) sofosbuvira i velpatasvira protiv replikona pune duljine ili kimeričkih replikona koji kodiraju sekvence NS5B i NS5A iz laboratorijskih sojeva navedene su u tablici 4.
The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 M in acutely infected cells and was 0.41 M in chronically infected cells (1 M = 0.50 g/ml).
Inhibitorna koncentracija amprenavira od 50% (IC50) kretala se u rasponu od 0,012 do 0,08 M kod akutno inficiranih stanica, a 0,41 M kod kronično inficiranih stanica (1 M = 0,50 g/ml).
The 50% primary generalised tonic-clonic seizures responder rate during the Maintenance Period was significantly higher in the perampanel group (58.0%) than in the placebo group (35.8%),
Stopa ispitanika s primarno generaliziranim toničko-kloničkim napadajima koji su imali 50% odgovora tijekom razdoblja terapije održavanja bila je značajno viša u skupini koja je primala perampanel (58,0%) nego u skupini koja je primala placebo (35,8%), P=0,0059.
The 500 mg film-coated tablets are yellow, oval and scored on one side.
500 mg filmom obložene tablete su žute, duguljaste tablete s razdjelnom crtom na jednoj strani.
The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50 - 80 % of the administered dose eliminated by renal excretion.
Glavni metabolit zidovudina u plazmi i urinu je 5’-glukuronid i u tom se obliku putem bubrega izlučuje približno 50 - 80% primijenjene doze lijeka.
The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50-80 % of the administered dose eliminated by renal excretion.
Glavni metabolit zidovudina u plazmi i urinu je 5'-glukuronid i u tom se obliku bubrezima izlučuje 50- 80% primijenjene doze lijeka.
The 5’-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50–80% of the administered dose eliminated by renal excretion.
Glavni metabolit zidovudina u plazmi i urinu je 5'-glukuronid i u tom se obliku bubrezima izlučuje 50- 80% primijenjene doze lijeka.
The 6 patients below 6 years were investigated through a single dose pharmacokinetic phase 3b trial (F13CD-3760) and then, included in the on-going long-term follow-up trial (F13CD-3835) assessing the safety and the efficacy of monthly replacement therapy with NovoThirteen.
6 bolesnika mlađih od 6 godina sudjelovalo je u 3.b fazi ispitivanja farmakokinetke pojedinačne doze (F13CD-3760), a potom su uključeni u dugotrajni nastavak ispitivanja koje je u tijeku (F13CD-3835) kako bi se procijenila sigurnost i djelotvornost mjesečnog nadomjesnog liječenja lijekom NovoThirteen.
The 60 mg capsules are blue and green and are printed with ‘60 mg’ and the code ‘9542’.
Kapsule od 60 mg su plave i zelene boje s otisnutim oznakom ‘60 mg’ i oznakom ‘9542’.
The 60 mg capsules have an opaque blue cap and opaque yellow body, imprinted in white ink with ‘MYLAN’ over ‘DL 60’ on both the cap and the body.
60 mg kapsule imaju neprozirnu plavu kapicu i neprozirno tijelo žute boje s oznakom "MYLAN" otisnutom bijelom tintom iznad oznake "DL 60" na kapici i na tijelu.
The 600 mg dose should be administered as a subcutaneous injection every three weeks.
Dozu od 600 mg treba primijeniti supkutanom injekcijom svaka tri tjedna.
The 649 randomised patients (641 treated) had Karnofsky Performance Status (KPS) of ≥ 70%, no CNS metastases and adequate organ function.
Randomizirano je 649 bolesnika (od kojih je 641 liječen) općeg statusa po Karnofskom ≥ 70%, bez metastaza u središnjem živčanom sustavu i sa zadovoljavajućom funkcijom organa.
The 64Cu gamma dose constant is 3.6 x 10-5 mSv x MBq-1 x h at a distance of 1 meter.
Konstanta 64Cu gama doze je 3,6 x 10-5 mSv x MBq-1 x h na udaljenosti od 1 metra.
The 6–mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions.
Metaboliti 6- merkaptopurina inhibiraju de novo sintezu purina i interkonverziju purinskih nukleotida.
The 7.5 ml dosing syringe has graduations from 0.8 ml to 7.5 ml.
Štrcaljka za doziranje od 7,5 ml je graduirana od 0,8 ml do 7,5 ml.
The 74 enrolled patients had a median age of 56 years (range: 43 to 68 years); 91.9% of the patients were male; 24.3% had a body mass index ≥ 30 kg/m2; 1.4% were Black; 95.9% had baseline HCV RNA levels ≥ 800,000 IU/ml; 10.8% had bridging fibrosis; none had cirrhosis; 38.9% had HCV genotype 1a; 58.3% had HCV genotype 1b; 2.8% had HCV genotype 1d; 21.6% had IL28B genotype CC; 54.1% had IL28B genotype CT; 24.3% had IL28B genotype TT; 28.4% (n = 21) were HCV treatment- naïve; 71.6% (n = 53) were treatment-experienced [14.9% (n = 11) were prior relapsers; 40.5% (n = 30) were prior non-responders; 16.2% (n = 12) could not be classified]; median time since liver transplantation was 2.5 years (range: 0.6 to 9.5 years); 67.6% (n = 50) received tacrolimus; 32.4% (n = 24) received cyclosporine A.
genotip CT; 24,3% imalo je IL28B genotip TT; 28,4% (n = 21) nije bilo prethodno liječeno za HCV infekciju; 71,6% (n = 53) bilo je prethodno liječeno [14,9% (n = 11) bili su bolesnici s prethodnim relapsom; 40,5% (n = 30) nisu prethodno odgovarali na liječenje; 16,2% (n = 12) nisu mogli biti klasificirani]; medijan vremena od transplantacije jetre bio je 2,5 godine (raspon: 0,6 do 9,5 godina); 67,6% (n = 50) primalo je takrolimus; 32,4% (n = 24) primalo je ciklosporin A.
The 740 enrolled patients had a median age of 51 years (range: 18 to 70); 60% of the patients were male; 21% had a body mass index ≥ 30 kg/m2; 5% were Black; 2% were Asian; 85% had baseline HCV RNA levels ≥ 800,000 IU/ml; 15% had bridging fibrosis; 14% had cirrhosis; 57% had HCV genotype 1a; and 43% had HCV genotype 1b.
740 uključenih bolesnika imalo je medijan dobi 51 godinu (raspon: 18 do 70); 60% bolesnika bili su muškarci; 21% je imalo indeks tjelesne mase ≥ 30 kg/m2; 5% je bilo crne rase; 2% je bilo azijatskog porijekla; 85% je imalo početne vrijednosti HCV RNK ≥ 800 000 IU/ml; 15% imalo je premoštavajuću fibrozu; 14% imalo je cirozu; 57% imalo je HCV genotip 1a i 43% imalo je HCV genotip 1b.
The 75 mg hard capsule consists of a grey opaque body bearing the imprint “ROCHE” and a light yellow opaque cap bearing the imprint “75 mg”.
Tvrda kapsula od 75 mg se sastoji od sivog neprozirnog tijela s natpisom "ROCHE" i svijetložute neprozirne kapice s natpisom "75 mg".
The 750 mg film-coated tablets are light red, oblong and scored on both sides.
750 mg filmom obložene tablete su svijetlocrvene, duguljaste tablete s razdjelnom crtom na obje strane.
The 8 mg tablets are blue, oval, biconvex, film-coated, and engraved on one side with the letters ‘FT’.
Tablete od 8 mg su plave, ovalne, bikonveksne, filmom obložene tablete s utisnutim slovima „FT“ na jednoj strani.
The 8-week treatment of ledipasvir/sofosbuvir without ribavirin was non-inferior to the 8-week treatment of ledipasvir/sofosbuvir with ribavirin (treatment difference 0.9%; 95% confidence interval:
Osmotjedno liječenje ledipasvirom/sofosbuvirom bez ribavirina nije bilo lošije od osmotjednog liječenja ledipasvirom/sofosbuvirom s ribavirinom (terapijska razlika 0,9 %; 95 % interval pouzdanosti: -3,9 % do 5,7 %) i 12-tjednog liječenja ledipasvirom/sofosbuvirom (terapijska razlika
The 80 mg capsules also contain red iron oxide (E172)
Kapsule od 80 mg također sadrže crveni željezov oksid (E172)
The 80 mg film-coated tablets are marked on one side with ‘80’.
S jedne strane filmom obloženih tableta od 80 mg nalazi se oznaka ‘80’.
The 95 % CI (-5.26, 3.99) for the difference in the estimated proportion of patients experiencing impending relapse by end of Week 26 excluded the predefined non-inferiority margin, 11.5 %.
Interval pouzdanosti (CI) od 95 % (−5,26, 3,99) za razliku u procijenjenom udjelu bolesnika koji su doživjeli prijeteći relaps do kraja 26. tjedna isključio je unaprijed definiranu marginu neinferiornosti, 11,5 %.
The 95 % confidence intervals for all subgroups include a hazard ratio of 1.
Interval pouzdanosti od 95% za sve podskupine uključivao je omjer hazarda 1.
The 95% confidence interval is stated in ‘[]’
95%-tni interval pouzdanosti naveden je u uglatim zagradama ‘[]’
The 95% confidence interval is stated in ‘[]’
95%-tni interval pouzdanosti naveden je u ‘[]’
The [90Y]-radiolabelled Zevalin solution must be prepared according to section 12.
Otopinu Zevalina radioaktivno označenog izotopom [90Y] potrebno je pripremiti u skladu s dijelom 12.
The A/lndonesia/05/2005 vaccine was shown to be efficacious with 100% survival, reduced incidence of fever, reduced weight loss, reduced virus burden, and reduced haematological (leukopenia and lymphopenia) changes in the vaccinated cohorts following homologous challenge.
Cjepivo A/lndonesia/05/2005 pokazalo se učinkovitim uz 100%-tno preživljavanje, smanjene incidencije vrućice, smanjenje gubitka težine, smanjenog virusnog opterećenja i smanjenih hematoloških (leukopenija i limfopenija) promjena u cijepljenim skupinama nakon homolognog izazova.
The A/Vietnam/1203/2004 vaccine afforded protection against homologous challenge as evidenced by full survivorship, reduced weight loss, a less pronounced and shorter increase in temperature, a less marked reduction in lymphocyte counts and in reduction of inflammation and necrosis in brain and olfactory bulb in the vaccinated cohorts as compared to control animals.
Cjepivo A/Vietnam/1203/2004 pružilo je zaštitu od homolognog izazova, o čemu svjedoči potpuno preživljavanje, smanjen gubitak težine, manje naglašeno i kraće povećanje temperature, manje primjetno smanjenje broja limfocita te smanjenje upale i nekroze mozga i olfaktornog bulbusa u cijepljenoj skupini u usporedbi s kontrolnim životinjama.
The ABASAGLAR cartridges are to be used only in conjunction with a reusable pen recommended for the use with Lilly insulin cartridges (see section 4.4).
ABASAGLAR ulošci smiju se koristiti samo s brizgalicom za višekratnu uporabu koja se preporučuje za uporabu s inzulinskim ulošcima tvrtke Lilly (vidjeti dio 4.4).
The ABASAGLAR cartridges are to be used only in pens recommended for Lilly insulin cartridges to ensure you get the correct dose.
ABASAGLAR ulošci smiju se upotrebljavati samo s brizgalicama koje se preporučuju za uporabu s inzulinskim ulošcima tvrtke Lilly kako bi se osigurala primjena točne doze.
The ABASAGLAR dose regimen (dose and timing) should be individually adjusted.
Režim doziranja lijeka ABASAGLAR (dozu i vrijeme primjene) potrebno je prilagoditi pojedinom bolesniku.
The abatacept + MTX group had less progression in structural damage compared with MTX group as reflected by mean treatment difference of the abatacept + MTX group versus MTX group (Table 5).
U skupini koja je primala abatacept + MTX zabilježena je manja progresija strukturnog oštećenja nego u skupini koja je primala samo MTX, što pokazuje srednja vrijednost razlike između liječenja abataceptom + MTX-om i liječenja samo MTX-om (Tablica 5).
The abatacept + MTX group had less progression in structural damage compared with MTX group as reflected by mean treatment difference of the abatacept + MTX group versus MTX group (Table 6).
U skupini koja je primala abatacept + MTX zabilježena je manja progresija strukturnog oštećenja nego u skupini koja je primala samo MTX, što pokazuje srednja vrijednost razlike između liječenja abataceptom + MTX-om i liječenja samo MTX-om (Tablica 6).
the abdomen (except for the area around the navel)
trbuh (osim područja oko pupka)
The ability of Bexsero to trigger the production of antibodies (immunogenicity) has been assessed in two main studies.
Sposobnost lijeka Bexsero da potakne stvaranje protutijela (imunogenost) procijenjena je u dva glavna ispitivanja.